Sign in
Taking people in United StatesNo phase

Safe and Explainable AI

Key facts

Who runs it
Abramson Cancer Center at Penn Medicine
Where
Philadelphia, United StatesSee the site
Trial code
Status
Recruiting
People taking part
300,000 people, planned
Started
29 Nov 2025
Expected to end
Nov 2028
Type of study
Observational, 3 groups
Treatments tested
  • AI-PERSONALIZED CLINICAL DECISION SUPPORT
Record updated
25 February 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Cardiology 18 years of age and older, admitted to any of the Penn Medicine hospitals from 2017 to the present. Sepsis 18 years of age at the time of presentation to an emergency department or admission to any Penn Medicine hospital from July 1, 2017, onward will be eligible as this represents the population at risk for acquiring sepsis Oncology 18 years of age and older with a diagnosis of invasive breast cancer (Stage 1-4) in the Penn Cancer registry

Who cannot take part

  • Cardiology Patients whose primary admission diagnosis was cardiac arrest Sepsis Those with pre-existing limitations on life-sustaining therapy will be excluded because their eligibility for sepsis definitions, care received, and outcomes, may be significantly and variably affected by pre-existing limitations on care. Oncology There are no other exclusions

This trial is currently available in United States.

  • Hospital of the University of PennsylvaniaPhiladelphia, United StatesContact: Haideliza Soto CalderonTaking people

About the trial

What the trial wants to find out

While current AI technology is suitable for automating some repetitive clinical tasks, technical challenges remain in solving critical and gainful problems in the domains of patient and disease management. The proposed research seeks to address issues in medical AI, such as integrating medical knowledge effectively, making AI recommendations explainable to clinicians, and establishing safety guarantees.

The 3 groups in the trial

  • Cardiology

    The primary objective in this clinical case scenario is to evaluate an ML model utilizing real-time cardiac telemetry, as well as other clinical, demographic, and imaging structured data sources, among hospitalized, intensive care unit (ICU) patients to predict impending inhospital cardiac arrest, identify potentially reversible causes of cardiac arrest, and predict which patients may have impending cardiac arrest due to shockable rhythms i.e. ventricular tachycardia (VT) or ventricular fibrillation (VF).

    Treatment: AI-PERSONALIZED CLINICAL DECISION SUPPORT

  • Oncology - Breast Cancer

    The primary objective in this clinical case scenario is to evaluate an ML model utilizing structured and unstructured data from clinical, demographic, and tumor molecular and germline sequencing, among outpatients with cancer, to predict short-term mortality and/or symptom decline. The model for prediction to treatment response in breast cancer patients will be compared with two prognostic tools: 1) Conversation Connect, a previously validated machine learning mortality prediction tool that has been used at the University of Pennsylvania for routine clinical decision support, and 2) the Elixhauser Comorbidity Index, a comorbidity-based prognostic index used commonly in research and risk-adjustment.

    Treatment: AI-PERSONALIZED CLINICAL DECISION SUPPORT

  • Sepsis

    The primary objective in this clinical case scenario is to develop and evaluate an ML model that utilizes multidmodal clinical data (e.g., structured EHR data such as demographics, laboratory test results, and vital signs; unstructured EHR data including the text of clinical encounter notes and, where available, waveforms from real-time cardiac, hemodynamic, and respiratory monitoring devices) to predict the need for initiation of broad-spectrum antimicrobial therapy for hospitalized patients with sepsis. With a focus on implementable and explainable AI, we will produce well calibrated predictions that are also clinically meaningful at the bedside to aid real-time decision-making about diagnosis and treatment initiation. The model for timely diagnosis and intervention in sepsis will be compared with widely used commercial and open-source sepsis prediction models.

    Treatment: AI-PERSONALIZED CLINICAL DECISION SUPPORT

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
SAFE AND EXPLAINABLE AI-ENABLED DECISION MAKING FOR PERSONALIZED CLINICAL DECISION SUPPORT
Record updated
25 February 2026